REVVITY, INC.

Listed Company

RVTYCIK 0000031791NYSELarge AcceleratedLaboratory Analytical InstrumentsMassachusettsFY ends Dec 29

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

$12.17B

Equity

$7.25B

Shares Out

111.56M

Op. Cash Flow

$582.93M

RVTY$113.77+12.73% · past yearDBEQ Basic

Daily closing prices

Business

Revvity is a leading provider of health science solutions, technologies, and services spanning discovery to development and diagnosis to cure, with specialized focus on translational multi-omics, biomarker identification, imaging, and diagnostics. The company offers a comprehensive portfolio of reagents, instruments, software, and services across life sciences research and clinical diagnostics. Revvity operates through two reportable segments—Life Sciences and Diagnostics—serving pharmaceutical, biotech, academic, and clinical laboratory customers globally across more than 160 countries.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Interest income	−31	−73	−72	−4	−2
Other components of net periodic pension cost (credit)	871,000	9	19	−33	—
Foreign exchange losses and other expense (income), net	15	7	38	8	—
Total interest and other expense, net	88	31	118	91	55
Interest Expense, Nonoperating	92	96	99	104	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	920	1,163	913	454	603
Accounts receivable, net	745	632	633	613	708
Inventories	379	368	428	405	426
Other current assets	196	186	337	122	148
Total current assets	2,240	2,350	3,001	3,289	2,441
Property, plant and equipment, net	479	482	510	483	486
Operating Lease, Right-of-Use Asset	165	168	155	188	164
Intangible assets, net	2,347	2,641	3,022	3,377	3,822
Beginning balance	6,613	6,464	6,534	6,482	6,627
Other assets, net	323	288	343	311	317
Total assets	12,168	12,392	13,565	14,130	15,001
Current portion of long-term debt	589	242,000	722	471	4
Accounts payable	185	167	204	273	325
Accrued expenses and other current liabilities	557	485	524	528	679
Total current liabilities	1,331	653	1,450	1,544	1,214
Long-term debt	2,631	3,150	3,178	3,923	4,980
Long-term liabilities	807	771	931	1,109	1,427
Operating Lease, Liability, Noncurrent	148	152	133	170	147
Total liabilities	4,918	4,726	5,692	6,747	7,859
Commitments and contingencies (see Note 16)	—	—	—	—	—
Preferred stock$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0	0	0	0
Common stock$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,281,000 and 120,646,000 shares at December 28, 2025 and December 29, 2024, respectively	112	121	123	126	126
Capital in excess of par value	1,306	2,097	2,417	2,753	2,761
Retained earnings	6,054	5,845	5,609	4,951	4,417
Accumulated other comprehensive loss	−222	−396	−277	−447	−163
Total stockholders' equity	7,250	7,667	7,873	7,383	7,141
Total liabilities and stockholders' equity	12,168	12,392	13,565	14,130	15,001

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Restructuring Charges and Changes in Estimates	56	17	27	14	—
Depreciation and amortization	405	428	432	427	311
Stock-based compensation	23	38	41	52	30
Pension and other post-retirement expense	4	9	23	−23	−29
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)	−1	−2	4	−1	3
Deferred taxes	−61	−102	−124	−106	−55
Contingencies and Non-Cash Tax Matters	−86,000	−8	26	−1	2
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts	5	6	7	7	5
Asset Impairment Charges	5	23	0	0	4
Change in fair value of investments	11	−8	34	16	—
Gain (Loss) on Extinguishment of Debt	0	0	−4	−3	0
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	273,000	−1	24	0	—
Accounts receivable, net	−101	−16	−9	66	166
Inventories, net	15	45	−14	−49	32
Accounts payable	7	−26	−76	−44	−8
Accrued expenses and other	−18	−21	−292	−237	—
Net cash provided by operating activities of continuing operations	589	665	279	673	1,330
Net cash used in operating activities of discontinued operations	−6	−37	−188	7	81
Net cash provided by operating activities	583	628	91	680	1,411
Capital expenditures	−74	−87	−81	−86	−86
Purchases of investments and notes receivables	−385,000	−7	−6	−47	—
Payments to Acquire Marketable Securities	0	0	−1,222	0	—
Proceeds from Sale and Maturity of Marketable Securities	0	710	550	0	—
Proceeds from Divestiture of Businesses	304,000	3	153,000	15	2
Cash paid for acquisitions, net of cash acquired	0	0	−2	−8	−3,982
Net cash (used in) provided by investing activities of continuing operations	−74	619	−761	−117	−4,090
Net cash provided by investing activities of discontinued operations	56	157	2,075	−16	−23
Net cash (used in) provided by investing activities	−17	776	1,314	−133	−4,113
Payments of Senior Debt	0	−711	−524	−58	−340
Payments of debt financing and equity issuance costs	−2	0	−15,000	0	−31
Proceeds from (Repayments of) Other Debt	−521,000	−12	6	−1	−14
Payments for acquisition-related contingent consideration	−4	−9	−10	−5,000	−2
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	3	8	4	14	25
Purchases of common stock	−821	−370	−389	−81	−73
Dividends paid	−33	−34	−35	−35	−32
Net cash (used in) provided by financing activities	−858	−1,128	−947	−662	2,942
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	49	−26	−14	−34	−23
Net (decrease) increase in cash, cash equivalents and restricted cash	−243	250	444	−149	217
Interest Paid, Excluding Capitalized Interest, Operating Activity	86	91	94	98	54
Income taxes	—	155	360	323	365
Consideration receivable from sale of Business	0	0	241	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is REVVITY, INC.'s CIK number?

REVVITY, INC.'s SEC CIK number is 0000031791 (31791). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find REVVITY, INC.'s SEC filings?

All of REVVITY, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did REVVITY, INC. last report earnings?

REVVITY, INC. (RVTY) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000031791-26-000016). This is REVVITY, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is REVVITY, INC.'s most recent earnings 8-K?

REVVITY, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0000031791-26-000016. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View REVVITY, INC.'s latest earnings 8-K →
Look up any company's CIK number →